Overview

A Study to Evaluate MK1903 in Patients With Dyslipidemia (MK1903-004)

Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the lipid-modifying effect and tolerability of MK1903 when compared to placebo in patients with dyslipidemia who are not on a statin or other lipid-modifying therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.